Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
NCT02323360 trial: what clinicians have said so far
A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC
- NCT02323360 ↗
- Terminated
- Istituto Clinico Humanitas
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02323360 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02323360 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomised Phase III Trial on Stereotactic Body Radiotherapy (SBRT) After Incomplete Transcatheter Arterial Embolization (TAE) or Chemoembolization (TACE) Versus Exclusive TAE or TACE for Inoperable Hepatocellular Carcinoma (HCC)
- Phase
- Phase not applicable
- Status
- Terminated
- Conditions
- Hepatocellular Carcinoma
- Interventions
- SBRT; TACE
- Arms
- Stereotactic body radiation therapy · Experimental
- TACE/TAE · Active comparator
- Enrollment
- 41
- Primary outcomes
- Local control (efficacy of SBRT in selected HCC patients with an incomplete response after TACE/TAE)
- Sponsor
- Istituto Clinico Humanitas
- Start
- Nov 2014
- Primary completion
- Oct 2019
- Results posted
- No
- Registry record
- NCT02323360 · updated Oct 25, 2019
Publications
linked from the registry- Comito T, Loi M, Franzese C, Clerici E, Franceschini D, Badalamenti M, Teriaca MA, Rimassa L, Pedicini V, Poretti D, Solbiati LA, Torzilli G, Ceriani R, Lleo A, Aghemo A, Santoro A, Scorsetti M. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360). Curr Oncol. 2022 Nov 16;29(11):8802-8813. doi: 10.3390/curroncol29110692. PubMed 36421345